

been published in *Nature Medicine* 1998 Jul 4(7): 844-847.

Inhibition of Ige-Mediated Allergies By A Human Ige-Derived Oligopeptide

EA Padlan, et al. (NIDDK).

DHHS Reference No. E-233-95/1; PCT/US97/22348 filed 05 Dec 97.

Licensing Contact: Stephen Finley, 301/496-7735 ext. 215.

It is estimated that 40 million people have some form of allergy and 14.9 million people have asthma in the United States. This technology identifies a specific amino acid sequence of the IgE molecule that when conformationally constrained inhibits the release of histamine and resulting inflammatory symptoms associated with hay fever and asthma, typical in people suffering from Type I hypersensitivity. This type of response occurs when an allergen triggers B cells to produce allergen-specific IgE antibodies. When binding to receptors on mast cells, these antibodies trigger the release of histamine and the resulting inflammatory symptoms. However when the IgE molecule is conformationally constrained by the addition of a cys residue at the amino acid terminal end and three amino acids at the carboxyl terminal end, the immune response is inhibited. The invention has applications for both of these high prevalence chronic diseases and could possibly be utilized as a vaccine for treatment of these problems.

Method of Treating Cancer Using C-26-Modified Epibryostatin

P Blumbert, Z Szallasi, GR Pettit (NCI).

Serial No. 60/013,740 filed 20 Mar 96; PCT/US97/04515 filed 30 Mar 97.

Licensing Contact: Girish Barua, 301/496-7735 ext. 263.

The invention relates to the use of 26-epibryostatin 1 and related compounds as cancer therapeutics. The compound is related to bryostatin 1 which has shown promise against melanoma but which has significant toxicity. The inventors have discovered that the antineoplastic activity of the bryostatins in a melanoma model system is not mediated by activation of protein kinase C (PKC) as previously believed. This has led to the discovery of antineoplastic activity in the lead compound, which with its reduced binding affinity for PKC would not have been expected to show such activity. The combination of antineoplastic activity with reduced affinity for PKC, which would be expected to translate into reduced toxicity compared to bryostatin 1, could lead to a significant clinical advantage

of 26-epibryostatin-1 and analogues over bryostatin 1.

Dated: July 31, 1998.

Jack Spiegel,

Director, Division of Technology Development and Transfer Office of Technology Transfer.

[FR Doc. 98-21649 Filed 8-12-98; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Mental Health; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Mental Health Special Emphasis Panel.

Date: August 11, 1998.

Time: 1:00 p.m. to 2:30 p.m.

Agenda: To review and evaluate grant applications.

Place: Parklawn Building—Room 9C-26, 5600 Fishers Lane, Rockville, MD 20857, (Telephone Conference Call).

Contact Person: Mary Sue Krause, Scientific Review Administrator, Division of Extramural Activities, National Institute of Mental Health, NIH, Parklawn Building, 5600 Fishers Lane, Room 9C-26, Rockville, MD 20857, 301-443-6470.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

(Catalogue of Federal Domestic Assistance Program Nos. 93.242, Mental Health Research Grants; 93.281, Scientific Development Award, Scientist Development Award of Clinicians, and Research Scientist Award; 93.282, Mental Health National Research Service Awards for Research Training, National Institutes of Health, HHS)

Dated: August 7, 1998.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 98-21647 Filed 8-12-98; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Mental Health; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Mental Health Special Emphasis Panel.

Date: August 19, 1998.

Time: 9:00 AM to 5:00 PM.

Agenda: To review and evaluate contract proposals.

Place: Hyatt Regency Bethesda, One Bethesda Metro Center, Bethesda, MD 20814.

Contact Person: Ron Schoenfeld, PHD, Scientific Review Administrator, Division of Extramural Activities, National Institute of Mental Health, NIH, Parklawn Building, 5600 Fishers Lane, Room 9-101, Rockville, MD 20857, 301-443-3936.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

Name of Committee: National Institute of Mental Health Special Emphasis Panel.

Date: August 21, 1998.

Time: 9:00 AM to 5:00 PM.

Agenda: To review and evaluate contract proposals.

Place: Hyatt Regency Bethesda, One Bethesda Metro Center, Bethesda, MD 20814.

Contact Person: Ron Schoenfeld, PHD, Scientific Review Administrator, Division of Extramural Activities, National Institute of Mental Health, NIH, Parklawn Building, 5600 Fishers Lane, Room 9-101, Rockville, MD 20857, 301-443-3936.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

Name of Committee: National Institute of Mental Health Special Emphasis Panel.

Date: August 25, 1998.

Time: 10:00 AM to 3:00 PM.

Agenda: To review and evaluate contract proposals.

Place: Ritz-Carlton Hotel at Pentagon City, 1250 South Hayes Street, Arlington, VA 22202.

Contact Person: Susan M Matthews, Scientific Review Administrator, Division of Extramural Activities, National Institute of